

Laura Moro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8818703/publications.pdf>

Version: 2024-02-01

42
papers

1,593
citations

361045

20
h-index

288905

40
g-index

43
all docs

43
docs citations

43
times ranked

2763
citing authors

#	ARTICLE	IF	CITATIONS
1	Expression and clinical implications of estrogen receptors in thoracic malignancies: a narrative review. <i>Journal of Thoracic Disease</i> , 2021, 13, 1851-1863.	0.6	7
2	Inhibition of the Histone Methyltransferase EZH2 Enhances Protumor Monocyte Recruitment in Human Mesothelioma Spheroids. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4391.	1.8	13
3	CDKN2A Determines Mesothelioma Cell Fate to EZH2 Inhibition. <i>Frontiers in Oncology</i> , 2021, 11, 678447.	1.3	10
4	Unsymmetric Cisplatin-Based Pt(IV) Conjugates Containing a PARP-1 Inhibitor Pharmacophore Tested on Malignant Pleural Mesothelioma Cell Lines. <i>Molecules</i> , 2021, 26, 4740.	1.7	8
5	Specific low-frequency electromagnetic fields induce expression of active KDM6B associated with functional changes in U937 cells. <i>Electromagnetic Biology and Medicine</i> , 2020, 39, 139-153.	0.7	0
6	A novel mutation of ABHD5 gene in a Chanarin Dorfman patient with unusual dermatological findings. <i>Lipids in Health and Disease</i> , 2019, 18, 232.	1.2	12
7	Mapping the minimum domain of the fibronectin binding site on transglutaminase 2 (TG2) and its importance in mediating signaling, adhesion, and migration in TG2-expressing cells. <i>FASEB Journal</i> , 2019, 33, 2327-2342.	0.2	12
8	Targeting estrogen receptor beta (ER β) for treatment of ovarian cancer: importance of KDM6B and SIRT1 for ER β expression and functionality. <i>Oncogenesis</i> , 2018, 7, 15.	2.1	38
9	Characterization of two ETFDH mutations in a novel case of riboflavin-responsive multiple acyl-CoA dehydrogenase deficiency. <i>Lipids in Health and Disease</i> , 2018, 17, 254.	1.2	29
10	Clinical and genetic characterization of a Chanarin Dorfman Syndrome patient born to diseased parents. <i>BMC Medical Genetics</i> , 2018, 19, 88.	2.1	15
11	Late onset of neutral lipid storage disease due to novel PNPLA2 mutations causing total loss of lipase activity in a patient with myopathy and slight cardiac involvement. <i>Neuromuscular Disorders</i> , 2017, 27, 481-486.	0.3	21
12	Tissue transglutaminase (TG2) enables survival of human malignant pleural mesothelioma cells in hypoxia. <i>Cell Death and Disease</i> , 2017, 8, e2592-e2592.	2.7	20
13	Expression and therapeutic significance of estrogen receptor β in malignant pleural mesothelioma. <i>Future Science OA</i> , 2017, 3, FSO0175.	0.9	6
14	KDM6B histone demethylase is an epigenetic regulator of estrogen receptor β expression in human pleural mesothelioma. <i>Epigenomics</i> , 2016, 8, 1227-1238.	1.0	15
15	SIRT1 at the crossroads of AKT1 and ER β in malignant pleural mesothelioma cells. <i>Oncotarget</i> , 2016, 7, 14366-14379.	0.8	16
16	Novel missense mutations in PNPLA2 causing late onset and clinical heterogeneity of neutral lipid storage disease with myopathy in three siblings. <i>Molecular Genetics and Metabolism</i> , 2015, 115, 110-117.	0.5	35
17	Intracellular lactate-mediated induction of estrogen receptor beta (ER β) in biphasic malignant pleural mesothelioma cells. <i>Oncotarget</i> , 2015, 6, 25121-25134.	0.8	18
18	Early onset of Chanarin-Dorfman syndrome with severe liver involvement in a patient with a complex rearrangement of ABHD5 promoter. <i>BMC Medical Genetics</i> , 2014, 15, 32.	2.1	20

#	ARTICLE	IF	CITATIONS
19	Agonist activation of estrogen receptor beta (ER β) sensitizes malignant pleural mesothelioma cells to cisplatin cytotoxicity. <i>Molecular Cancer</i> , 2014, 13, 227.	7.9	18
20	Negative modulation of mitochondrial oxidative phosphorylation by epigallocatechin-3 gallate leads to growth arrest and apoptosis in human malignant pleural mesothelioma cells. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2013, 1832, 2085-2096.	1.8	56
21	Therapies currently in Phase II trials for malignant pleural mesothelioma. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 1255-1263.	1.9	15
22	PARP1 inhibition affects pleural mesothelioma cell viability and uncouples AKT/mTOR axis via SIRT1. <i>Journal of Cellular and Molecular Medicine</i> , 2013, 17, 233-241.	1.6	33
23	Circulating tumor cells as a diagnostic test for malignant pleural mesothelioma. <i>Expert Opinion on Medical Diagnostics</i> , 2012, 6, 171-173.	1.6	3
24	Perifosine as a Potential Novel Anti-Cancer Agent Inhibits EGFR/MET-AKT Axis in Malignant Pleural Mesothelioma. <i>PLoS ONE</i> , 2012, 7, e36856.	1.1	36
25	Coordinated Sumoylation and Ubiquitination Modulate EGF Induced EGR1 Expression and Stability. <i>PLoS ONE</i> , 2011, 6, e25676.	1.1	32
26	Deficit of complex I activity in human skin fibroblasts with chromosome 21 trisomy and overproduction of reactive oxygen species by mitochondria: involvement of the cAMP/PKA signalling pathway. <i>Biochemical Journal</i> , 2011, 435, 679-688.	1.7	115
27	Estrogen Receptor β Exerts Tumor Repressive Functions in Human Malignant Pleural Mesothelioma via EGFR Inactivation and Affects Response to Gefitinib. <i>PLoS ONE</i> , 2010, 5, e14110.	1.1	56
28	Clinical and genetic characterization of chnarin-dorfman syndrome patients: first report of large deletions in the ABHD5 gene. <i>Orphanet Journal of Rare Diseases</i> , 2010, 5, 33.	1.2	47
29	Estrogen Receptor- β Affects the Prognosis of Human Malignant Mesothelioma. <i>Cancer Research</i> , 2009, 69, 4598-4604.	0.4	87
30	Flavonoid-induced autophagy in hormone sensitive breast cancer cells. <i>FASEB J</i> , 2009, 23, 327-332.	1.1	15
31	Convergence of integrins and EGF receptor signaling via PI3K/Akt/FoxO pathway in early gene Egr1 expression. <i>Journal of Cellular Physiology</i> , 2009, 118, 294-303.	2.0	57
32	8-Prenylningenin inhibits epidermal growth factor-induced MCF-7 breast cancer cell proliferation by targeting phosphatidylinositol-3-OH kinase activity. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2009, 113, 163-170.	1.2	23
33	8-Prenylningenin, inhibits estrogen receptor- α mediated cell growth and induces apoptosis in MCF-7 breast cancer cells. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2007, 107, 140-148.	1.2	39
34	Estrogenic Analogues Synthesized by Click Chemistry. <i>ChemMedChem</i> , 2007, 2, 437-440.	1.6	38
35	Nongenomic effects of 17 β -estradiol in human platelets: potentiation of thrombin-induced aggregation through estrogen receptor β and Src kinase. <i>Blood</i> , 2005, 105, 115-121.	0.6	97
36	p130Cas interacts with estrogen receptor α and modulates non-genomic estrogen signaling in breast cancer cells. <i>Journal of Cell Science</i> , 2004, 117, 1603-1611.	1.2	120

#	ARTICLE	IF	CITATIONS
37	Integrin-induced Epidermal Growth Factor (EGF) Receptor Activation Requires c-Src and p130Cas and Leads to Phosphorylation of Specific EGF Receptor Tyrosines. <i>Journal of Biological Chemistry</i> , 2002, 277, 9405-9414.	1.6	330
38	Genomic organisation and chromosomal localisation of the gene encoding human beta adducin. <i>Gene</i> , 1995, 167, 313-316.	1.0	19
39	Correction of the defective extracellular matrix of Ehlers-Danlos syndrome skin fibroblasts by dexamethasone.. <i>Cell Biology International</i> , 1994, 18, 29-38.	1.4	7
40	Quantitative Evaluation of mRNAs by In Situ Hybridization and Image Analysis: Principles and Applications. <i>DNA and Cell Biology</i> , 1993, 12, 629-636.	0.9	15
41	Exclusion of stromelysin-1, stromelysin-2, interstitial collagenase and fibronectin genes as the mutant loci in a family with recessive epidermolysis bullosa dystrophica and a form of cerebellar ataxia. <i>Human Genetics</i> , 1992, 89, 503-7.	1.8	17
42	Study of fibronectin mRNA in human laryngeal and ectocervical carcinomas by IN SITU hybridization and image analysis. <i>International Journal of Cancer</i> , 1992, 51, 692-697.	2.3	22